

January 19, 2024

Chemiloids Life Sciences Pvt. Ltd.: Moved to Issuer Non-Cooperating category, Ratings downgraded based on best available information

Summary of rating action

Instrument^	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Long-term – Fund-based – Cash credit	10.00	10.00	[ICRA]B+(Stable); ISSUER NOT COOPERATING*; Rating downgraded from [ICRA]BB+(Stable) and moved to 'Issuer Not Cooperating' Category.
Total	10.00	10.00	

^{*}Issuer did not cooperate; based on best available information.

Rationale

ICRA has downgraded and moved the bank loan ratings for **Chemiloids Life Sciences Pvt. Ltd. (CLSPL)** to the 'Issuer Not Cooperating' category. The rating is denoted as "[ICRA]B+(Stable); ISSUER NOT COOPERATING"

The rating downgrade is because of lack of adequate information regarding **Chemiloids Life Sciences Pvt. Ltd.** performance and hence the uncertainty around its credit risk. ICRA assesses whether the information available about the entity is commensurate with its rating and reviews the same as per its "Policy in respect of non-cooperation by a rated entity" available at www.icra.in. The lenders, investors and other market participants are thus advised to exercise appropriate caution while using this rating as the rating may not adequately reflect the credit risk profile of the entity, despite the downgrade.

As part of its process and in accordance with its rating agreement with **Chemiloids Life Sciences Pvt. Ltd.**, ICRA has been trying to seek information from the entity so as to monitor its performance, but despite repeated requests by ICRA, the entity's management has remained non-cooperative. In the absence of requisite information and in line with the aforesaid policy of ICRA, a rating view has been taken on the entity based on the best available information.

Please refer to the following link for the previous detailed rationale that captures the Key rating drivers and their description, Liquidity position, Rating sensitivities: Click here. ICRA is unable to provide the latest information because of non-cooperation by the entity.

Analytical approach

Analytical Approach	Comments	
Applicable rating methodologies	Corporate Credit Rating Methodology Policy in respect of Non-cooperation by a rated entity Rating Methodology - Pharmaceuticals	
Parent/Group support Not Applicable		
Consolidation/Standalone For arriving at the ratings, ICRA has considered standalone financials of CLSPL		

www.icra .in Page | 1

[^]Instrument details are provided in Annexure-1



About the company

CLSPL was established in 1976 as a partnership firm by Mr. G. Ganga Raju and his family. The partnership firm was converted into a private limited company in 2014. It is involved in manufacturing of herbal extract products, which are used in ayurvedic formulations. The company manufactures more than 400 herbal extracts such as *amla*, *ashwagandha*, *tulsi*, etc. CLSPL is a part of the Laila Group of Companies, which is into diverse businesses such as sugar, paper, nutraceuticals, hotels, education, etc.

Key financial indicators (audited)

	FY2022	FY2023
Operating income (Rs. crore)	62.6	62.0
PAT (Rs. crore)	7.5	7.6
OPBDIT/OI (%)	19.0%	19.3%
PAT/OI (%)	11.9%	12.3%
Total outside liabilities/Tangible net worth (times)	0.7	0.5
Total debt/OPBDIT (times)	1.0	0.2
Interest coverage (times)	13.8	23.5

Source: Company data; PAT: Profit after tax; OPBDIT: Operating profit before depreciation, interest, taxes and amortisation; Amount in Rs.crore

Status of non-cooperation with previous CRA: Not Applicable

Any other information: None

Rating history for past three years

		Current Rating (FY2024)			Chronology of Rating History for the past 3 years			
		Type Ra	Amount	Amount	Date & Rating in	Date & Rating in	Date & Rating in	Date & Rating
	Instrument		Rated	Outstanding as of March 31, 2023 (Rs. crore)	Date & Rating III	FY2023	FY2022	in FY2021
			(Rs.		Jan 19, 2024	Oct 28, 2022	Jul 30, 2021	-
1	Cash credit	Long term	10.00	-	[ICRA]B+(Stable); ISSUER NOT COOPERATING	[ICRA]BB+(Stable)	[ICRA]BB+(Stable)	-

Complexity level of the rated instrument

Instrument	Complexity Indicator	
Long-term – Fund-based – Cash Credit	Simple	

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional, or legal aspects. Details on the complexity levels of the instruments, is available on ICRA's website: Click Here

www.icra.in



Annexure-I: Instrument details

ISIN No	Instrument Name	Date of Issuance / Sanction	Coupon Rate	Maturity Date	Amount Rated (RS Crore)	Current Rating and Outlook
NA	Cash Credit	NA	NA	NA	10.00	[ICRA]B+(Stable); ISSUER NOT COOPERATING

Source: Company

Annexure-II: List of entities considered for consolidated analysis: Not Applicable



ANALYST CONTACTS

Shamsher Dewan

+91 124 4545328

shamsherd@icraindia.com

Nithya Debbadi

+91 40 69396416

nithya.debbadi@icraindia.com

Srikumar K

+91 44 4596 4318

ksrikumar@icraindia.com

Raviteja Etikala

+91 40 69396418

etikala.teja@icraindia.com

RELATIONSHIP CONTACT

L. Shivakumar

+91 22 6114 3406

shivakumar@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860

communications@icraindia.com

Helpline for business queries

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in



ICRA Limited



Registered Office

B-710, Statesman House, 148, Barakhamba Road, New Delhi-110001 Tel: +91 11 23357940-45



© Copyright, 2024 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.